UNSPSC 51273304: Biphenamine or xenysalate

This classification denotes an astringent with the molecular formula C19H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 65X88IL51X, chemically known as (1,1-biphenyl)-3-carboxylic acid, 2-hydroxy-, 2-(diethylamino)ethyl ester but generally known as biphenamine, which bears US NIH Compound Identifier 21720. Biphenamine most often comes in base, hydrochloride, and q forms. European Medicines Agency schedules Xenysalate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00108MIG.

UNSPSC 51273304 Biphenamine or xenysalate, a Commodity code, shows minimal relevant recent state and local procurement activity. The three most recent opportunities tagged to this code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical distribution — none of which concern biphenamine or xenysalate specifically. The code appears to be a narrow pharmaceutical ingredient classification that does not match the actual scope of work state and local governments are soliciting under related pharmaceutical and health-supply categories.

Seminole County, Florida posted an IFB (IFB60459723LAS) in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023; the Texas Health and Human Services Commission issued an RFI in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP in January 2026 for generic multi-source pharmaceuticals and over-the-counter products with proposals due March 26, 2026, distributed through three authorized wholesalers across participating state and local facilities in Minnesota and Oregon. These opportunities reflect state health agencies and county public-health procurement focused on broadline pharmaceutical supply, drug-safety systems, and cost-management mechanisms rather than specialty chemical intermediates. The code does not surface dedicated biphenamine or xenysalate demand in the recent activity block, suggesting limited routine state and local government use of this ingredient under its nominal classification.